Suzanne Lentzsch, M.D., Ph.D.
New Patients Tel - 646-317-4805
New Patient Email - Hemoncnewpatients@columbia.edu
Administrative Office Tel - 646-317-4840
Fax - 212-305-6762
Outpatients Office Location
Herbert Irving Pavilion, 9th Floor
161 Fort Washington Ave at W 165th St.
New York, NY
Dr. Lentzsch is an Associate Professor of Clinical Medicine at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital/ Columbia University Medical Center in Manhattan. She is the Director of the Multiple Myeloma and Amyloidosis Service at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charité Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA.Dr Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI. Since March 2012, Dr. Lentzsch is the Director of the Multiple Myeloma and Amyloidosis Service at Columbia University Medical Center, College of Physicians and Surgeons. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom’sMacroglobulinemia.
Dr Lentzsch has a high interest in clinical research. She is the principal investigator of many phase 1, 2 and 3 clinical trials, including investigator-initiated studies for newly diagnosed and relapsed/refractory multiple myeloma, for maintenance following transplant for multiple myeloma and amyloidosis. Dr Lentzsch also served as national principal investigator in Germany evaluating the role of lenalidomide in the treatment of relapsed Multiple Myeloma. As Co-Chair of the Pathways Committee, she played a major role in the development of the Multiple Myeloma Pathways at University Pittsburgh Medical Center.
Dr Lentzsch' translational laboratory research work provided critical insights to understanding of the mechanism of action of thalidomide and IMiDs in multiple myeloma and bone disease. Her research is funded by various grants and awards from e.g. the Pennsylvania Department of Health, the German Cancer Foundation, the Leukemia and Lymphoma Society and the Multiple Myeloma Research Foundation. As a frequent lecturer, Dr. Lentzsch regularly presents at annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, of which he is also a member. Dr Lentzsch has published over 50 original articles, editorials, chapters, many as the lead or senior author, in such prestigious journals as Journal of Clinical Investigations, Blood, Cancer Research, and Leukemia.
- Hematologic Malignancies with a Focus on Multiple Myeloma and Amyloidosis
- Stem Cell Transplantation
- Experimental Therapeutics
- Internal Medicine (Germany)
- Hematology and Oncology (Germany)
- Associate Professor of Clinical Medicine, Columbia University Medical Center
- Director, Multiple Myeloma and Amyloidosis Service, Columbia University Medical Center
- M.D., 1990, Humboldt University, School of Medicine, Berlin, Germany
- Ph.D., 1994, Humboldt University, School of Medicine, Berlin, Germany
Internship and Residency
- University Medical Center Charite, Humboldt University, Berlin/Germany, Department of Medicine, Hematology, Oncology and Tumorimmunology 1990-1998
- University Medical Center Charite, Humboldt University, Department of Medicine, Hematology, Oncology and Tumorimmunology 1990 - 1998
- Dana-Farber Cancer Institute, Boston, MA, Boston, Harvard University 1999-2001